



OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.

Visit [go.covermymeds.com/OptumRx](http://go.covermymeds.com/OptumRx) to begin using this free service.

Please note: All information below is required to process this request.

Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

## Rydapt® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)	Provider Information (required)
-------------------------------	---------------------------------

Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)
-----------------------------------

Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting <b>brand</b>		Directions for Use:	
<input type="checkbox"/> Check if request is for <b>continuation of therapy</b>			

Clinical Information (required)
---------------------------------

**Select the diagnosis below:**

- Acute myeloid leukemia (AML)
- Aggressive systemic mastocytosis (ASM)
- Mast cell leukemia (MCL)
- Systemic mastocytosis with associated hematological neoplasm (SM-AHN)
- Other diagnosis: \_\_\_\_\_ ICD-10 Code(s): \_\_\_\_\_

**Clinical Information:**

Is Rydapt prescribed by or in consultation with a hematologist or oncologist?  Yes  No

Is this request for continuation of prior Rydapt therapy?  Yes  No

Has the patient used Rydapt within the past 120 days?  Yes  No

**For acute myeloid leukemia (AML), also answer the following:**

Does the patient have newly diagnosed disease?  Yes  No

Does the patient have FMS-like tyrosine kinase 3 (FLT3) mutation-positive disease, as detected by a U.S. Food and Drug Administration (FDA)-approved test?  Yes  No

Will Rydapt be used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation?  Yes  No

**Quantity Limit:**

What is the quantity requested per MONTH? \_\_\_\_\_

**What is the reason for exceeding the plan limitations?**

- Titration or loading-dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- There is a medically necessary justification why the patient cannot use a higher commercially available strength to achieve the same dosage and remain within the same dosing frequency. **Please specify:** \_\_\_\_\_
- Other: \_\_\_\_\_

**Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?**

---

Please note: This request may be denied unless all required information is received.  
 If the patient is not able to meet the above standard prior authorization requirements, please call 1-800-711-4555.  
 For urgent or expedited requests please call 1-800-711-4555.  
 This form may be used for non-urgent requests and faxed to 1-800-527-0531.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Rydapt\_CMS\_2019Feb-W